Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
19 Julho 2023 - 9:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-classi therapeutics that
combine both targeted and immune-mediated mechanisms, announced
today that in vivo and in vitro data on the unique mechanism of
TPST-1495, the company’s novel dual receptor inhibitor of
prostaglandin E2 (PGE2) signaling, were published in Cancer
Research Communications, a journal of the American Association for
Cancer Research.
“While the biology of PGE2 in promoting tumor
growth and immune suppression is well established, there are still
no approved drugs for cancer that effectively block the
prostaglandin pathway,” said Tom Dubensky, Ph.D., president of
Tempest. “Our innovation with TPST-1495 shows for the first time
the effect of blocking PGE2 signaling through the EP2 and EP4
pro-tumor receptors while maintaining the important anti-tumor
signaling of PGE2 through the EP1 and EP3 receptors, which could be
an important advance to inhibiting PGE2. Additionally, these
results further support what we believe is an innovative and robust
pipeline at Tempest that includes TPST-1120, a novel PPAR⍺
antagonist, which has shown early positive data from an ongoing
global randomized study in first-line HCC patients.”
About TPST-1495
Described in the Cancer Research Communications
publication, TPST-1495 is an orally-available and potent small
molecule designed to block the receptors EP2 and EP4 in the
prostaglandin pathway. PGE2 both promotes tumor cell growth and has
strong immune-suppressive signaling through these receptors.
Several malignancies are thought to be prostaglandin driven through
expression of high levels of COX-2, the cellular enzyme that
produces PGE2, including endometrial, bladder, breast, colorectal,
and cervical cancers. Tempest has conducted multiple studies with
peripheral blood mononuclear cells (PBMCs) from healthy adult
donors and in several mouse tumor models that demonstrate a
significant increase in immune activation and anti-tumor potency by
inhibiting both EP2 and EP4, when compared to EP4-only targeted
molecules and non-steroidal anti-inflammatory drugs (NSAIDS), such
as celecoxib.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two clinical programs, TPST-1120 and TPST-1495, target
PPARα and EP2/EP4, respectively, and are advancing through trials
designed to study the agents as monotherapies and in combination
with approved agents. TPST-1495 is currently being evaluated in
combination with pembrolizumab in a Phase 1b expansion cohort in
patients with advanced endometrial cancer. TPST-1120 is being
evaluated in first line hepatocellular carcinoma (HCC) in
combination with atezolizumab and bevacizumab, the standard of care
for first-line HCC, in a Phase 1b/2 randomized global study where
an early data cut demonstrated positive results in multiple
categories; the company expects to receive the first full data set
in the second half of 2023. Tempest is also developing an orally
available inhibitor of TREX1, a target that controls activation of
the cGAS/STING pathway. Tempest is headquartered in Brisbane,
California. More information about Tempest can be found on the
company’s website at www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking
statements (including within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and Section 27A of the
Securities Act of 1933, as amended (the “Securities Act”))
concerning Tempest Therapeutics, Inc. These statements may discuss
goals, intentions, and expectations as to future plans, trends,
events, results of operations or financial condition, or otherwise,
based on current beliefs of the management of Tempest Therapeutics,
as well as assumptions made by, and information currently available
to, management of Tempest Therapeutics. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “could”, “expect,”
“anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,”
“intend,” and other similar expressions. All statements that are
not historical facts are forward-looking statements, including any
statements regarding: the design, initiation, progress, timing,
scope and results of clinical trials; anticipated therapeutic
benefit and regulatory development of Tempest Therapeutic’s product
candidates; the Company’s ability to deliver on potential
value-creating milestones; the Company’s guidance regarding cash
runway, as well as our operational plans. Forward-looking
statements are based on information available to Tempest
Therapeutics as of the date hereof and are not guarantees of future
performance. Any factors may cause differences between current
expectations and actual results, including: unexpected safety or
efficacy data observed during preclinical or clinical trials;
clinical trial site activation or enrollment rates that are lower
than expected; changes in expected or existing competition; changes
in the regulatory environment; and unexpected litigation or other
disputes. Other factors that may cause actual results to differ
from those expressed or implied are discussed in greater detail in
the “Risk Factors” section of the Company’s Quarterly Report on
Form 10-Q for the quarter ended March 31, 2023 and other
documents filed by the Company from time to time with the
Securities and Exchange Commission. Except as required by
applicable law, Tempest Therapeutics undertakes no obligation to
revise or update any forward-looking statement, or to make any
other forward-looking statements, whether as a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing Tempest
Therapeutics’ views as of any date subsequent to the date of this
press release and should not be relied upon as prediction of future
events. In light of the foregoing, investors are urged not to rely
on any forward-looking statement in reaching any conclusion or
making any investment decision about any securities of Tempest
Therapeutics.
Investor Contacts:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
———————————————i If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Tempest Therpeutics (NASDAQ:TPST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024